At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 143 enrolled
Drug / intervention
SPM 962drug
Likely dose
SPM 962 36.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-label Long-term Extension Trial From Phase II/III of SPM962 (243-07-001) in Early Parkinson's Disease Patients With Non-concomitant Treatment of L-dopa
In Brief
A Phase 3 clinical trial evaluating SPM 962 for Parkinson's Disease. Completed, enrolled 143 participants across 7 sites.
Detailed Summary
Safety of SPM 962 in a once-daily repeated long-term treatment in Parkinson's disease patients who are not concomitantly treated with L-dopa will be investigated with a doses.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson's Disease
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
Primary CompletionOct 2010
First PostedJun 2012
TodayJul 2026
First PostedJun 27, 2012
Enrollment StartJan 1, 2008
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 14.0 years ago
Interventions
SPM 962drug
SPM 962 transdermal patch once a daily up to 36.0 mg/day